{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:24:17Z","timestamp":1787498657977,"version":"build-2736575974"},"reference-count":114,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiology Clinics"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.ccl.2010.11.003","type":"journal-article","created":{"date-parts":[[2011,1,22]],"date-time":"2011-01-22T04:37:36Z","timestamp":1295671056000},"page":"137-156","source":"Crossref","is-referenced-by-count":38,"title":["Renin-Angiotensin-Aldosterone Blockade for Cardiovascular Disease Prevention"],"prefix":"10.1016","volume":"29","author":[{"given":"Krishnaswami","family":"Vijayaraghavan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Deedwania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccl.2010.11.003_bib1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1748-1716.1898.tb00272.x","article-title":"Niere und Kreislauf","volume":"8","author":"Tigerstedt","year":"1898","journal-title":"Skand Arch Physiol"},{"key":"10.1016\/j.ccl.2010.11.003_bib2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1126\/science.127.3292.242-a","article-title":"Suggested revision of nomenclature\u2014angiotensin","volume":"127","author":"Braun-Menendez","year":"1958","journal-title":"Science"},{"key":"10.1016\/j.ccl.2010.11.003_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1084\/jem.71.1.29","article-title":"A\u00a0crystalline pressor substance (angiotonin) resulting from the reaction between renin and renin-activator","volume":"71","author":"Page","year":"1940","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.ccl.2010.11.003_bib4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1084\/jem.104.2.193","article-title":"The amino acid sequence of hypertensin. II","volume":"104","author":"Skeggs","year":"1956","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.ccl.2010.11.003_bib5","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1021\/bi00311a006","article-title":"Primary structure of human preangiotensinogen deduced from the cloned cDNA sequence","volume":"23","author":"Kageyama","year":"1984","journal-title":"Biochemistry"},{"key":"10.1016\/j.ccl.2010.11.003_bib6","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1113\/jphysiol.1940.sp003850","article-title":"The substance causing renal hypertension","volume":"98","author":"Braun-Menendez","year":"1940","journal-title":"J\u00a0Physiol"},{"key":"10.1016\/j.ccl.2010.11.003_bib7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1084\/jem.99.3.275","article-title":"The existence of two forms of hypertensin","volume":"99","author":"Skeggs","year":"1957","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.ccl.2010.11.003_bib8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1084\/jem.106.3.439","article-title":"The preparation, purification, and amino acid sequence of a polypeptide renin substrate","volume":"106","author":"Skeggs","year":"1957","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.ccl.2010.11.003_bib9","first-page":"293","article-title":"Mechanisms regulating the secretion and metabolism of aldosterone in experimental secondary hyperaldosteronism","volume":"17","author":"Davis","year":"1959","journal-title":"Recent Prog Horm Res"},{"key":"10.1016\/j.ccl.2010.11.003_bib10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/080370598437411","article-title":"The renin-angiotensin system\u2014a century of progress","volume":"7","author":"Hedner","year":"1998","journal-title":"Blood Press"},{"key":"10.1016\/j.ccl.2010.11.003_bib11","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1152\/physrev.1990.70.4.1067","article-title":"Morphology, physiology, and molecular biology of renin secretion","volume":"70","author":"Hackenthal","year":"1990","journal-title":"Physiol Rev"},{"key":"10.1016\/j.ccl.2010.11.003_bib12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-201X.2004.01308.x","article-title":"Controlling the release and production of renin","volume":"181","author":"Persson","year":"2004","journal-title":"Acta Physiol Scand"},{"key":"10.1016\/j.ccl.2010.11.003_bib13","doi-asserted-by":"crossref","first-page":"306S","DOI":"10.1016\/S0895-7061(97)00388-9","article-title":"Preclinical pharmacology of angiotensin II receptor antagonists: update and outstanding issues","volume":"10","author":"Johnston","year":"1997","journal-title":"Am J Hypertens"},{"issue":"Suppl 2","key":"10.1016\/j.ccl.2010.11.003_bib14","first-page":"47","article-title":"Physiologic and pharmacologic implications of AT1 versus AT2 receptors","volume":"5","author":"Chung","year":"1996","journal-title":"Blood Press"},{"key":"10.1016\/j.ccl.2010.11.003_bib15","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.ph.50.030188.002205","article-title":"Regulation of aldosterone secretion","volume":"50","author":"Quinn","year":"1988","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.ccl.2010.11.003_bib16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0031-6997(25)00446-6","article-title":"Angiotensin II receptors and angiotensin II receptor antagonists","volume":"45","author":"Timmermans","year":"1993","journal-title":"Pharmacol Rev"},{"issue":"Suppl 7","key":"10.1016\/j.ccl.2010.11.003_bib17","first-page":"S3","article-title":"Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence","volume":"16","author":"Unger","year":"1998","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.ccl.2010.11.003_bib18","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1152\/physrev.00036.2005","article-title":"Physiology of local renin-angiotensin systems","volume":"86","author":"Paul","year":"2006","journal-title":"Physiol Rev"},{"key":"10.1016\/j.ccl.2010.11.003_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0002-9343(84)80056-X","article-title":"Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients","volume":"77","author":"B\u00fchler","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.ccl.2010.11.003_bib20","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1172\/JCI111828","article-title":"Correction of abnormal renal blood flow response to angiotensin II by converting enzyme inhibition in essential hypertensives","volume":"75","author":"Redgrave","year":"1985","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ccl.2010.11.003_bib21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ki.1992.4","article-title":"Transgenic rats carrying the mouse renin gene\u2014morphological characterization of a low-renin hypertension model","volume":"41","author":"Bachmann","year":"1992","journal-title":"Kidney Int"},{"key":"10.1016\/j.ccl.2010.11.003_bib22","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1378\/chest.86.1.40","article-title":"Renin and the complications of acute myocardial infarction","volume":"86","author":"Vaney","year":"1984","journal-title":"Chest"},{"key":"10.1016\/j.ccl.2010.11.003_bib23","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1136\/hrt.72.3_Suppl.S65","article-title":"Neuroendocrine activation after myocardial infarction","volume":"72","author":"Remes","year":"1994","journal-title":"Br Heart J"},{"key":"10.1016\/j.ccl.2010.11.003_bib24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0002-9149(00)00957-7","article-title":"Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure","volume":"86","author":"Isnard","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccl.2010.11.003_bib25","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1161\/01.CIR.85.6.2004","article-title":"ACE inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease","volume":"85","author":"Perondi","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2010.11.003_bib26","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1161\/01.CIR.90.4.2056","article-title":"Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection","volume":"90","author":"Lonn","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2010.11.003_bib27","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1161\/01.CIR.83.6.1849","article-title":"Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system","volume":"83","author":"Weber","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2010.11.003_bib28","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0735-1097(92)90167-L","article-title":"The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure","volume":"20","author":"Packer","year":"1992","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccl.2010.11.003_bib29","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-101-3-370","article-title":"The neurohumoral axis in congestive heart failure","volume":"101","author":"Francis","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ccl.2010.11.003_bib30","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/ki.1987.156","article-title":"Renal and circulatory mechanisms in congestive heart failure","volume":"31","author":"Dzau","year":"1987","journal-title":"Kidney Int"},{"key":"10.1016\/j.ccl.2010.11.003_bib31","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1161\/01.CIR.101.10.1130","article-title":"Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts","volume":"101","author":"Kawano","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2010.11.003_bib32","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1006\/jmcc.2000.1129","article-title":"Induction of cardiac fibrosis by aldosterone","volume":"32","author":"Lijnen","year":"2000","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.ccl.2010.11.003_bib33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1046\/j.1365-2796.1999.00449.x","article-title":"Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options","volume":"245","author":"Britten","year":"1999","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.ccl.2010.11.003_bib34","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1161\/01.CIR.94.11.2756","article-title":"Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease","volume":"94","author":"Diet","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2010.11.003_bib35","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1161\/01.HYP.32.6.965","article-title":"Effect of activation and inhibition of the rennin-angiotensin system on plasma PAI-1","volume":"32","author":"Brown","year":"1998","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.ccl.2010.11.003_bib36","doi-asserted-by":"crossref","first-page":"41A","DOI":"10.1016\/S0002-9149(97)00457-8","article-title":"Multiple signaling pathways involved in the metabolic effects of insulin","volume":"80","author":"Moule","year":"1997","journal-title":"Am J Cardiol"},{"issue":"Suppl 4","key":"10.1016\/j.ccl.2010.11.003_bib37","first-page":"S84","article-title":"Angiotensin II stimulates insulin-independent glucose uptake in hypertrophied rat hearts [abstract]","volume":"15","author":"Nascimben","year":"1997","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.ccl.2010.11.003_bib38","doi-asserted-by":"crossref","first-page":"19626","DOI":"10.1016\/S0021-9258(17)32215-9","article-title":"Angiotensin II-induced protein tyrosine phosphorylation in neonatal rat","volume":"269","author":"Schorb","year":"1994","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.ccl.2010.11.003_bib39","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/380541a0","article-title":"Tyrosine kinases in activation of the MAP-kinase cascade by G protein-coupled receptors","volume":"380","author":"Wan","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.ccl.2010.11.003_bib40","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1042\/bj3100741","article-title":"Angiotensin II induces tyrosine phosphorylation of insulin receptor substrate 1 and its association with phosphatidylinositol 3-kinase in rat heart","volume":"310","author":"Saad","year":"1995","journal-title":"Biochem J"},{"issue":"9","key":"10.1016\/j.ccl.2010.11.003_bib41","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2165\/00003495-200262090-00002","article-title":"The role of the angiotensin system in cardiac glucose homeostasis: therapeutic implications","volume":"62","author":"Bernobich","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.ccl.2010.11.003_bib42","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","article-title":"Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial","volume":"353","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2010.11.003_bib43","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","article-title":"Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 Study","volume":"354","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2010.11.003_bib44","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2010.11.003_bib45","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2010.11.003_bib46","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(98)08127-6","article-title":"Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA group","volume":"353","author":"Gueyffier","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2010.11.003_bib47","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1097\/00004872-200312000-00030","article-title":"Results of the pilot study for the Hypertension in the Very Elderly Trial","volume":"21","author":"Bulpitt","year":"2003","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.ccl.2010.11.003_bib48","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","article-title":"Treatment of hypertension in patients 80 years of age or older","volume":"358","author":"Beckett","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2010.11.003_bib49","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa042739","article-title":"PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease","volume":"351","author":"Braunwald","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2010.11.003_bib50","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0140-6736(95)90865-X","volume":"345","author":"ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2010.11.003_bib51","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0735-1097(95)00498-X","article-title":"Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 trial","volume":"27","author":"Gruppo Italiano per lo Studio della Sopravvivenza nell\u2019Infarto Miocardico","year":"1996","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccl.2010.11.003_bib52","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"The CONSENSUS Trial Study Group","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2010.11.003_bib53","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1056\/NEJM199209033271002","article-title":"Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)","volume":"327","author":"Swedberg","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2010.11.003_bib54","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1161\/01.CIR.90.4.1731","article-title":"Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE investigators","volume":"90","author":"Rutherford","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2010.11.003_bib55","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A\u00a0clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study group","volume":"333","author":"Kober","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2010.11.003_bib56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)09374-X","article-title":"Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril cardiac evaluation","volume":"354","author":"Torp-Pedersen","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2010.11.003_bib57","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/eurheartj\/18.1.41","article-title":"Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study investigators","volume":"18","author":"Cleland","year":"1997","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ccl.2010.11.003_bib58","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJM199501123320203","article-title":"The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-term Evaluation (SMILE) study investigators","volume":"332","author":"Ambrosioni","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2010.11.003_bib59","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0002-9149(01)01461-8","article-title":"The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function","volume":"87","author":"Pitt","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccl.2010.11.003_bib60","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/01.CIR.97.22.2202","article-title":"Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials","volume":"97","author":"ACE Inhibitor Myocardial Infarction Collaborative Group","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2010.11.003_bib61","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","article-title":"Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group","volume":"355","author":"Flather","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2010.11.003_bib62","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0735-1097(00)00638-0","volume":"35","author":"Latini","year":"2000","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccl.2010.11.003_bib63","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0002-9343(03)00435-2","article-title":"Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction","volume":"115","author":"Rodrigues","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.ccl.2010.11.003_bib64","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jacc.2005.11.073","article-title":"Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials","volume":"47","author":"Al-Mallah","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccl.2010.11.003_bib65","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators","volume":"325","author":"The SOLVD Investigators","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2010.11.003_bib66","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"The SOLVD Investigators","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2010.11.003_bib67","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A\u00a0comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure","volume":"325","author":"Cohn","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2010.11.003_bib68","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S1071-9164(99)90001-5","article-title":"Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group","volume":"5","author":"Carson","year":"1999","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.ccl.2010.11.003_bib69","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","article-title":"Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack","volume":"358","author":"PROGRESS Collaborative Group","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2010.11.003_bib70","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/bmj.324.7339.699","article-title":"Heart outcomes prevention evaluation. Use of ramipril in preventing stroke: double blind randomised trial","volume":"324","author":"Bosch","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.ccl.2010.11.003_bib71","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2010.11.003_bib72","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2010.11.003_bib73","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2010.11.003_bib74","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2010.11.003_bib75","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(97)01187-2","article-title":"Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)","volume":"349","author":"Pitt","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2010.11.003_bib76","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2010.11.003_bib77","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0002-8703(00)90037-1","article-title":"Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors","volume":"139","author":"Granger","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.ccl.2010.11.003_bib78","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2010.11.003_bib79","doi-asserted-by":"crossref","first-page":"693","DOI":"10.7326\/0003-4819-141-9-200411020-00011","article-title":"Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction","volume":"141","author":"Lee","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ccl.2010.11.003_bib80","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","article-title":"The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial","volume":"21","author":"Lithell","year":"2003","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.ccl.2010.11.003_bib81","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","article-title":"Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial","volume":"372","author":"Yusuf","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2010.11.003_bib82","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2010.11.003_bib83","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/01.STR.0000166048.35740.a9","article-title":"Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES)","volume":"6","author":"Schrader","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.ccl.2010.11.003_bib84","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1056\/NEJMoa0804593","article-title":"Telmisartan to prevent recurrent stroke and cardiovascular events","volume":"359","author":"Yusuf","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2010.11.003_bib85","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s11886-000-0077-3","article-title":"Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure","volume":"2","author":"Ennezat","year":"2000","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.ccl.2010.11.003_bib86","first-page":"H1769","article-title":"Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations","volume":"273","author":"Balcells","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ccl.2010.11.003_bib87","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1161\/CIRCULATIONAHA.104.475673","article-title":"Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets","volume":"115","author":"Brown","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2010.11.003_bib88","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1161\/01.HYP.0000161880.59963.da","article-title":"Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension","volume":"45","author":"Doulton","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.ccl.2010.11.003_bib89","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(03)12229-5","article-title":"Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial","volume":"361","author":"Nakao","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2010.11.003_bib90","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0828-282X(09)70490-8","article-title":"2009 Canadian Hypertension Education Program recommendations: the scientific summary\u2014an annual update","volume":"25","author":"Campbell","year":"2009","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ccl.2010.11.003_bib91","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/archinte.167.18.1930","article-title":"Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials","volume":"167","author":"Phillips","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ccl.2010.11.003_bib92","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1464-5491.2007.02097.x","article-title":"Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis","volume":"24","author":"Jennings","year":"2007","journal-title":"Diabet Med"},{"key":"10.1016\/j.ccl.2010.11.003_bib93","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2010.11.003_bib94","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2215\/CJN.03350708","article-title":"Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D)","volume":"4","author":"Fried","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"16","key":"10.1016\/j.ccl.2010.11.003_bib95","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1001121","article-title":"Effect of valsartan on the incidence of diabetes and cardiovascular events. NAVIGATOR Study Group","volume":"362","author":"McMurray","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2010.11.003_bib96","first-page":"2388","volume":"19","author":"Dickstein","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ccl.2010.11.003_bib97","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/eurheartj\/ehn543","article-title":"Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials","volume":"30","author":"Ezekowitz","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ccl.2010.11.003_bib98","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1161\/CIRCULATIONAHA.109.192065","volume":"119","author":"Hunt","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2010.11.003_bib99","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.18553\/jmcp.2007.13.s8-b.9","article-title":"The Renin-Angiotensin Aldosterone System: Pathophysiological role and pharmacologic inhibition","volume":"13","author":"Atlas","year":"2007","journal-title":"J\u00a0Manag Care Pharm"},{"key":"10.1016\/j.ccl.2010.11.003_bib100","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1177\/00912700022009693","article-title":"An overview of antihypertensive therapy in the 20th century","volume":"40","author":"Piepho","year":"2000","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.ccl.2010.11.003_bib101","doi-asserted-by":"crossref","first-page":"21","DOI":"10.18553\/jmcp.2007.13.s8-b.21","article-title":"Direct renin inhibition: focus on aliskiren","volume":"13","author":"Pool","year":"2007","journal-title":"J\u00a0Manag Care Pharm"},{"key":"10.1016\/j.ccl.2010.11.003_bib102","first-page":"623","article-title":"Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor","volume":"60","author":"Buczko","year":"2008","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.ccl.2010.11.003_bib103","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/01.HYP.0000179574.10913.08","article-title":"Renin inhibition: new potential for an old therapeutic target","volume":"46","author":"Kelly","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.ccl.2010.11.003_bib104","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0140-6736(06)69442-7","article-title":"Oral renin inhibitors","volume":"368","author":"Staessen","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2010.11.003_bib105","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00004872-200502000-00025","article-title":"Aliskiren: a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats","volume":"23","author":"Wood","year":"2005","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.ccl.2010.11.003_bib106","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/01.CIR.0000156466.02908.ED","article-title":"Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients","volume":"111","author":"Gradman","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2010.11.003_bib107","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(07)61508-6","article-title":"Dual inhibition of the renin system by aliskiren and valsartan","volume":"370","author":"Oparil","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2010.11.003_bib108","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/HJH.0b013e3282f3ad9a","article-title":"Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial","volume":"26","author":"Andersen","year":"2008","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.ccl.2010.11.003_bib109","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCHEARTFAILURE.107.740704","article-title":"effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure","volume":"1","author":"McMurray","year":"2008","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ccl.2010.11.003_bib110","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMe0803375","article-title":"Aliskiren and dual therapy in type 2 diabetes mellitus","volume":"358","author":"Ingelfinger","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2010.11.003_bib111","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/ncpneph0962","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"4","author":"Parving","year":"2008","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.ccl.2010.11.003_bib112","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/ndt\/gfn721","article-title":"Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): Rationale and study design","volume":"24","author":"Parving","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ccl.2010.11.003_bib113","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/CIRCULATIONAHA.108.826214","article-title":"Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy","volume":"119","author":"Solomon","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2010.11.003_bib114","first-page":"S886","article-title":"The AGELESS Study: The effect of aliskiren vs ramipril alone or in combination with hydrochlorothiazide and amlodipine in patients \u226565 years of age with systolic hypertension","volume":"118","author":"Daniel","year":"2008","journal-title":"Circulation"}],"container-title":["Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865110001190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865110001190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T20:52:24Z","timestamp":1740862344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733865110001190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":114,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S0733865110001190"],"URL":"https:\/\/doi.org\/10.1016\/j.ccl.2010.11.003","relation":{},"ISSN":["0733-8651"],"issn-type":[{"value":"0733-8651","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}